Tumor Necrosis Factor-alpha clinical trials at UCSF

1 research study open to eligible people

Tumor necrosis factor-alpha is an immune protein that promotes inflammation. UCSF is evaluating infliximab in patients with large vertebrobasilar aneurysms that can compress the brainstem. UCSF is collecting data on inflammation, brain imaging, and hemorrhage or ischemic events.

Showing trials for

  • Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

    open to eligible people ages 18 years and up

    Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

    San Francisco, California

Our lead scientists for Tumor Necrosis Factor-alpha research studies include .

Last updated: